Viewing nowCombinationEusitamet XR Extended-Release Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youyoung Pharmaceutical Co., Ltd.

MFDS item code 202201932 · Approved 2022.05.11 · Insurance code 648204590
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar in patients with type 2 diabetes. It is suitable for patients who are also on dietary and exercise therapy, and effectively improves blood sugar levels through the combination of sitagliptin and metformin. This facilitates better blood sugar management and helps prevent complications. Therefore, this medication plays an important role in the treatment of diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, a healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication contains sitagliptin and metformin and is used for the treatment of diabetes. Before taking this medication, it is essential to check for any allergic reactions. If symptoms of hypersensitivity such as skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult a physician. If symptoms of pancreatitis, such as abdominal pain, nausea, or vomiting occur, discontinue the medication and notify healthcare professionals immediately. Patients with severe renal impairment, acute heart failure, severe infections, or dehydration should not use this medication. Before and after tests using iodine contrast agents, this medication should be temporarily discontinued due to the risk of renal function deterioration and lactic acidosis, and it may only be resumed once renal function has been confirmed to be normal. Women who are pregnant or may become pregnant, or who are breastfeeding, should not take this medication. For elderly patients, regular monitoring of renal function is recommended, and starting with the minimum dose is advised. Though rare, lactic acidosis can occur as a serious side effect; thus, if symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, or abnormal changes in consciousness occur, inform healthcare professionals immediately. Excessive alcohol consumption should be avoided while taking this medication, as alcohol intake may increase the risk of lactic acidosis. Additionally, symptoms of hypoglycemia such as dizziness, tremors, and cold sweats may occur. Therefore, careful monitoring of blood sugar levels is essential, especially when taken with other hypoglycemic agents. If surgery is planned, the medication should be discontinued 48 hours prior to surgery and can be resumed after oral intake has normalized and renal function has recovered. This medication can cause vitamin B12 deficiency; hence, regular blood tests to monitor vitamin B12 levels are necessary for long-term use. Regular monitoring of renal function and hematological tests should be conducted while taking this medication, and any unusual symptoms should be reported to healthcare providers immediately. Finally, this medication is not recommended for children (under 18 years old) as its safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly sealed container. It is also recommended to store it at room temperature between 1 and 30 degrees Celsius. This helps maintain the medication's efficacy over time.
Bright green, oval-shaped, biconvex extended-release film-coated tablets
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youyoung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.